Overview on Causes and Updated Management of Favism

Sheikh, Mohammed Hussen; Hazazi, Ahlam Shary J; Alanazi, Ashwaq Nafea O.; Hazazi, Ibtisam Shary J.; Qaysi, Amal Abutaleb M.; Alali, Yara Abdulrahman; Alshehri, Badaya Awadh M.; Almutari, Ohoud; Bedaiwi, Rawan Hamdi; Alatawi, Rawan Hamoud M.; Alqarni, Rahf Mohammed; Alharbi, Alanoud; Alshehri, Rawan Ahmed H.; Alrashidi, Rinad Rasheed M.; Balawi, Mona Awad O. Al

doi:10.9734/jpri/2021/v33i47b33121

Cited by 2 publications

(2 citation statements)

References 7 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to meeting or exceeding dietary requirements for all essential minerals except calcium (AEGIC, 2021), they contain relatively high levels of beneficial antioxidant and phenolic compounds, which may provide protection against reactive oxygen species, as well as anti‐hypertensive and anti‐cancer effects (Martineau‐Côté, Achouri, Karboune, et al, 2022; Martineau‐Côté, Achouri, Wanasundara, et al, 2022; Siah et al, 2012; Turco et al, 2016). However, the presence of anti‐nutritional factors, principally the pyrimidine glycosides vicine and convicine, can also negatively impact on the health benefits associated with this crop (Duc et al, 1999; Khazaei et al, 2019; Wang & Ueberschär, 1990) and cause haemolytic anaemia in individuals with favism (Cappellini & Fiorelli, 2008; Pulkkinen et al, 2016; Sheikh et al, 2021). Consequently, there is a widespread need for closely monitoring the levels of both health‐benefitting and anti‐nutritive compounds in faba bean.…”

Section: Introductionmentioning

confidence: 99%

Assessment of bioactive compounds in faba bean using infrared spectroscopy

Johnson,

Walsh,

Naiker

2023

Legume Science

View full text Add to dashboard Cite

Faba bean (Vicia faba) is growing in popularity in Australia, partly due to its higher levels of health‐benefiting compounds compared to other grain crops. This study investigated infrared spectroscopy for predicting levels of bioactive compounds such as antioxidants and phenolics in faba bean flour. Calibration models were performed on 60 samples of faba bean, comprising 10 varieties grown across two field locations in 1 year. For model validation, an independent test set comprising the same varieties grown in a different year was utilised. Near‐infrared spectroscopy (NIRS) showed promise for the prediction of total phenolic content, with an R2pred of 0.66 and root mean square error of prediction (RMSEP) of 76 mg/100 g. Similarly, prediction of ferric reducing antioxidant power, a measure of antioxidant activity, gave an R2pred of 0.59 and RMSEP of 87 mg/100 g. Additionally, moving window optimisation was used to determine the most important wavelength region for the prediction of these analytes. Fourier transform infrared spectroscopy did not yield any suitable models for the analytes investigated. Although the NIRS models developed were not capable of exactly quantifying phenolic or antioxidant content, infrared spectroscopy appears useful for rapidly discriminating between samples containing high and low levels of phenolics or antioxidant compounds. With further refinement, this technique could potentially be applied for the quality assurance of phenolic content or antioxidant capacity in faba bean seeds.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of bioactive compounds in faba bean using infrared spectroscopy

Johnson,

Walsh,

Naiker

2023

Legume Science

View full text Add to dashboard Cite

show abstract

“…G6PD was first discovered in horse erythrocytes in 1931 by Warburg and Christian 5 . According to the World Health Organization G6PD Deficiency Working Group (WHO-G6PD) criteria (biochemical, kinetic, clinical), over 400 G6PD variants have been identified 6,7 . According to the screening studies conducted in the Çukurova region, the rate of G6PD deficiency was reported to be 8.2% 8 .…”

Section: Introductionmentioning

confidence: 99%

Comparison of gene expressions in individuals with G6PD Mediterranean mutation and hemolytic anemia

GÜNAŞTI,

TULİ

2023

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: In our study, we aimed to clarify the relationship between Glucose-6-phosphate dehydrogenase (G6PD) enzyme kinetics and mRNA expression levels of the G6PD gene in Gd-Med patients with and without hemolytic anemia. Materials and Methods: The study group consisted of 30 cases with Gd-Med mutation and 30 cases with enzyme activity levels in the reference range. G6PD activity was determined by the Beutler method. G6PD enzyme was partially purified with DE-52 anion exchange resin, and its kinetic parameters were studied. Gd-Med mutation was genotyped by MboII enzyme digest and sequence analysis. The expression level of the G6PD gene was calculated according to the 2-ΔΔCt formula. Results: In our study, a significant difference was found between the KmNADP+ and KmG6P values of the cases with Gd-Med mutation and the control group. There was no significant difference between KmNADP+ and KmG6P values in Gd-Med mutated patients with and without hemolytic anemia. Gene expression results of 18 patients without hemolytic anemia were significantly higher than 12 patients with hemolytic anemia. In addition, there was a significant difference between these variables and the control group. Conclusion: It might be a possible explanation that the substrate binding site of the enzyme in cases with Gd-Med mutation may have undergone post-transcriptional or post-translational modifications, and therefore gene expression might be changed. As a further study, the decrease in gene expressions of patients with hemolytic anemia with Gd-Med mutation can be clarified by evaluating the promoter side of the gene.

show abstract

Overview on Causes and Updated Management of Favism

Cited by 2 publications

References 7 publications

Assessment of bioactive compounds in faba bean using infrared spectroscopy

Assessment of bioactive compounds in faba bean using infrared spectroscopy

Comparison of gene expressions in individuals with G6PD Mediterranean mutation and hemolytic anemia

Contact Info

Product

Resources

About